Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects

Next Previous
Trial Profile

A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of ABX-002 in Healthy Adult Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ABX-002 (Primary)
  • Indications Major depressive disorder
  • Focus Adverse reactions; First in man
  • Sponsors Autobahn Therapeutics

Most Recent Events

  • 07 Nov 2023 According to an Autobahn Therapeutics media release, Based on the Phase 1 results, Autobahn plans to submit an investigational new drug (IND) application to the U.S. Food and Drug Administration and advance into a Phase 2 clinical study to evaluate ABX-002 as an adjunctive treatment for individuals with MDD in the first half of 2024.
  • 07 Nov 2023 Results presented in an Autobahn Therapeutics media release.
  • 13 Sep 2023 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top